Y.H. Park

2.3k total citations · 2 hit papers
62 papers, 1.4k citations indexed

About

Y.H. Park is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Y.H. Park has authored 62 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Y.H. Park's work include HER2/EGFR in Cancer Research (25 papers), Cancer Treatment and Pharmacology (24 papers) and Advanced Breast Cancer Therapies (23 papers). Y.H. Park is often cited by papers focused on HER2/EGFR in Cancer Research (25 papers), Cancer Treatment and Pharmacology (24 papers) and Advanced Breast Cancer Therapies (23 papers). Y.H. Park collaborates with scholars based in South Korea, United States and United Kingdom. Y.H. Park's co-authors include Javier Cortés, Rebecca Dent, Vassiliki Karantza, Konstantinos Tryfonidis, Joohyuk Sohn, Theodoros Foukakis, Sherko Küemmel, Peter Schmid, Sherene Loi and S.B. Kim and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Nature Communications.

In The Last Decade

Y.H. Park

59 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

2020 279 citations Y.H. Park, S.B. Kim et al. Annals of Oncology profile →
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

2024 47 citations Lajos Pusztai, Carsten Denkert et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Y.H. Park South Korea	21	1.1k	389	295	253	224	62	1.4k
Ulrich Andergassen Germany	21	1.3k 1.1×	434 1.1×	894 3.0×	280 1.1×	548 2.4×	73	1.8k
S-A. Im South Korea	18	799 0.7×	454 1.2×	242 0.8×	114 0.5×	324 1.4×	85	1.1k
Dana M. Roque United States	20	480 0.4×	156 0.4×	134 0.5×	165 0.7×	348 1.6×	61	1.1k
Christoph A. Schatz Germany	15	525 0.5×	346 0.9×	173 0.6×	84 0.3×	503 2.2×	47	1.2k
Joshua Z. Drago United States	9	742 0.7×	255 0.7×	111 0.4×	95 0.4×	356 1.6×	28	1.1k
Lindsey Rolfe United States	12	622 0.5×	199 0.5×	174 0.6×	78 0.3×	374 1.7×	30	856
Éric Charpentier United States	15	652 0.6×	164 0.4×	178 0.6×	186 0.7×	401 1.8×	22	1.0k
Sven Golfier Germany	16	469 0.4×	244 0.6×	85 0.3×	182 0.7×	477 2.1×	24	1.3k
Shoichiro Ohtani Japan	19	939 0.8×	399 1.0×	375 1.3×	177 0.7×	371 1.7×	92	1.4k
Andreas Zoephel Austria	8	776 0.7×	949 2.4×	148 0.5×	96 0.4×	798 3.6×	10	1.8k

Countries citing papers authored by Y.H. Park

Since Specialization

Citations

This map shows the geographic impact of Y.H. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y.H. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y.H. Park more than expected).

Fields of papers citing papers by Y.H. Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y.H. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y.H. Park. The network helps show where Y.H. Park may publish in the future.

Co-authorship network of co-authors of Y.H. Park

This figure shows the co-authorship network connecting the top 25 collaborators of Y.H. Park. A scholar is included among the top collaborators of Y.H. Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y.H. Park. Y.H. Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmid, Peter, Hao‐Chien Wang, Y.H. Park, et al.. (2025). 555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study. Annals of Oncology. 36. S413–S414. 1 indexed citations

Barroso‐Sousa, Romualdo, Y.H. Park, C. Saura Manich, et al.. (2025). LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest. Annals of Oncology. 36. S1563–S1564.

Park, Y.H., Joonghyuk Kim, Hye‐Jin Moon, et al.. (2025). The degradation mechanism of multi-resonance thermally activated delayed fluorescence materials. Nature Communications. 16(1). 392–392. 15 indexed citations

Pusztai, Lajos, Carsten Denkert, Joyce O’Shaughnessy, et al.. (2024). Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Annals of Oncology. 35(5). 429–436. 47 indexed citations breakdown →

Schmid, Peter, Heather L. McArthur, Baojun Xu, et al.. (2024). LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial. Annals of Oncology. 35. S1212–S1213. 5 indexed citations

Kidd, Jesse B., Wesley B. Swords, Y.H. Park, et al.. (2024). Enantioselective Paternò–Büchi Reactions: Strategic Application of a Triplet Rebound Mechanism for Asymmetric Photocatalysis. Journal of the American Chemical Society. 146(22). 15293–15300. 21 indexed citations

Kim, Jae Hyeon, Kyung-Hun Lee, Y.H. Park, et al.. (2024). Survival outcomes of young-age female patients with early breast cancer: an international multicenter cohort study. ESMO Open. 9(11). 103732–103732. 3 indexed citations

Gelmon, Karen A., PA Fasching, Suzette Delaloge, et al.. (2023). 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial. ESMO Open. 8(1). 101392–101392. 1 indexed citations

Park, Y.H., et al.. (2023). The impact of comorbid anxiety on quantitative EEG heterogeneity in children with attention-deficit/hyperactivity disorder. Frontiers in Psychiatry. 14. 1190713–1190713. 1 indexed citations

10.

Modi, Shanu, William Jacot, Hiroji Iwata, et al.. (2023). 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. Annals of Oncology. 34. S334–S335. 28 indexed citations

11.

Schmid, Peter, Javier Cortés, Rebecca Dent, et al.. (2023). LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. Annals of Oncology. 34. S1257–S1257. 20 indexed citations

12.

Cardoso, Fátima, Heather L. McArthur, Peter Schmid, et al.. (2023). LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. Annals of Oncology. 34. S1260–S1261. 67 indexed citations

13.

Swords, Wesley B., Hanna Lee, Y.H. Park, et al.. (2023). Highly Enantioselective 6π Photoelectrocyclizations Engineered by Hydrogen Bonding. Journal of the American Chemical Society. 145(49). 27045–27053. 16 indexed citations

14.

Fehm, Tanja, Fabrice André, Ian E. Krop, et al.. (2023). 186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC). ESMO Open. 8(1). 101375–101375. 4 indexed citations

15.

Park, Y.H., Takashi Kurogi, Patrick J. Carroll, et al.. (2021). Phosphorus‐Atom Transfer from Phosphaethynolate to an Alkylidyne. Angewandte Chemie. 133(46). 24616–24622. 1 indexed citations

16.

Park, Y.H., Takashi Kurogi, Patrick J. Carroll, et al.. (2021). Phosphorus‐Atom Transfer from Phosphaethynolate to an Alkylidyne. Angewandte Chemie International Edition. 60(46). 24411–24417. 8 indexed citations

17.

Tolaney, Sara M., Romualdo Barroso‐Sousa, Y.H. Park, et al.. (2021). 328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Annals of Oncology. 32. S507–S508. 16 indexed citations

18.

Park, Y.H., KH Lee, Kyung Hae Jung, et al.. (2017). A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial. Annals of Oncology. 28. v74–v74. 3 indexed citations

19.

Saeki, Toshiaki, Hirofumi Mukai, Jungsil Ro, et al.. (2017). A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Annals of Oncology. 28. v80–v81. 7 indexed citations

20.

Won, Young‐Woong, et al.. (2010). A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Annals of Oncology. 22(2). 417–423. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact